消息

Orion S.A. (OEC) trades at a 19.84‑times forward 12‑month earnings multiple, below the industry average, reflecting market pricing for a challenging 2026. Management has set 2026 adjusted EBITDA to $160‑$200 million, down from $248 million in 2025, due to a contract pricing reset in the Rubber segment and weaker Western tire builds. The decline is...

全文

ALK Abello’s quarterly results are expected to provide valuable information about the company’s performance in the first quarter of 2026. As a global specialty pharmaceutical company focused on allergy treatments, ALK’s results may have implications for investors and analysts following the stock. The presentation will offer an opportunity for these...

全文

The meeting will be audio webcast live on ALK’s website, allowing participants to follow along remotely. For those who prefer to join via telephone, registration is required through a designated link, which will also provide dial‑in details and passcodes. The presentation slides will be available on the company’s website shortly before the meeting...

全文

ALK Abello will publish its first‑quarter 2026 results on May 5, 2026. The company's management team, consisting of Peter Halling, Claus Steensen Sølje, and Per Plotnikof, will hold a presentation for investors and analysts at 1:30 p.m. CEST the same day. During the presentation, they will discuss the results and provide insight into ALK’s outlook.

全文

Market reactions included a 1.4% drop in CDNS shares immediately after results and a 2.8% rise in after‑hours trading, with a year‑to‑date share gain of 6.5% versus the S&P 500’s 4.7%. Zacks ranking placed the stock at #4 (sell) due to unfavorable estimate revisions. The company’s backlog and AI‑driven demand remain key catalysts for its accelerate...

全文

Analyst commentary was mixed. Citi raised its target to $400 from $385; Baird to $385 from $381; Wells Fargo to $400 from $375; Loop Capital to $400 from $365; KeyBanc to $425 from $405; Deutsche Bank to $375 from $371; Piper Sandler to $325 from $319. The FactSet mean price target stands at $380.90, with an average rating of buy or overweight. BNP...

全文

Q2 2026 guidance cites revenue of $1.555 billion–$1.595 billion and non‑GAAP EPS of $2.02–$2.08. Days sales outstanding remained stable at 67 days. Cadence highlighted strategic collaborations with Google to optimize its ChipStack AI super‑agent and partnerships with NVIDIA to expand AI and robotics capabilities.

全文

Cadence raised its fiscal‑2026 revenue outlook to $6.125 billion–$6.225 billion, a 17% YoY increase, but trimmed adjusted diluted earnings per share to $7.85–$7.95 from the previously guided $8.05–$8.15. GAAP diluted net income per share is now projected at $4.39–$4.49. Operating margin guidance was lowered to 27.5–28.5% GAAP and 43.5–44.5% non‑GAA...

全文

Cadence Design Systems (CDNS) reported first‑quarter 2026 results on March 28 2026 that surpassed consensus estimates. Revenue of $1.474 billion represented an 18‑19% year‑over‑year increase, with a GAAP operating margin of 29.3% and a non‑GAAP margin of 44.7%. Net income per share on a non‑GAAP basis was $1.96. Bookings rose 21.4% YoY to $1.49 bil...

全文

Crinetics Pharmaceuticals (CRNX) received European Commission approval for PALSONIFY (paltusotine) on 27 member states and 3 EEA countries, making it the first once‑daily oral therapy for adult acromegaly in the EU. Approval was grounded in two Phase 3 studies that showed rapid onset, reliable biochemical control of IGF‑1, sustained efficacy and no...

全文